ArticleBMC immunology2026
Prevalence and clinical correlates of autoimmune and infection-related antibodies in unexplained seizures in western China.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnexplained seizures represent a substantial diagnostic and therapeutic challenge in clinical neurology. Immune-mediated mechanisms coupled with prior infections are increasingly recognized as pivotal etiological contributors, yet large-scale epidemiological data from western China remain scarce.
methodsThis retrospective cohort study enrolled 471 patients with unexplained seizures from eight provinces in western China between January 2017 and June 2022. Serum and cerebrospinal fluid samples were tested for neural-specific autoantibodies, thyroid peroxidase antibody (TPO-Ab), thyroglobulin antibody (TgAb), antinuclear antibody (ANA), and immunoglobulin M/G antibodies against Toxoplasma gondii, rubella virus, cytomegalovirus, and herpes simplex virus. Patients were stratified into definite autoimmune-associated seizures (AAS), probable AAS, and non-AAS subgroups.
trial registrationThis trial was registered with the Chinese Clinical Trial Registry (ChiCTR1900027074) on October 30, 2019, and was retrospectively registered as the first participant was enrolled in January 2017.
resultsOverall, 14.65% of patients tested positive for neural-specific autoantibodies, with N-methyl-D-aspartate receptor antibody (NMDAR-Ab) being the most prevalent subtype (accounting for 46.38% of antibody-positive patients), and leucine-rich glioma-inactivated 1 antibody (LGI1-Ab) predominantly detected in patients with recurrent seizures. The positive rates of TPO-Ab, TgAb, and ANA were significantly higher in the definite AAS group than in the non-AAS group (all P < 0.01). No significant differences in pathogen-specific IgM levels were observed among subgroups, while serum HSV-IgG and T. gondii-IgG levels were markedly lower in the non-AAS group (both P < 0.0001). CSF white blood cell count was significantly elevated in the definite AAS group (P = 0.036).
conclusionCombined detection of neural autoantibodies, systemic autoimmune antibodies, and infection-related serological markers facilitates etiological diagnosis and identification of candidates for early immunotherapy in patients with unexplained seizures in western China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.